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The results of administering escalating, i.v. doses of targeted
nanoparticles containing a siRNA targeting the M2 subunit of
ribonucleotide reductase to non-human primates are reported. The
nanoparticles consist of a synthetic delivery system that uses a
linear, cyclodextrin-containing polycation, transferrin (Tf) protein
targeting ligand, and siRNA. When administered to cynomolgus
monkeys at doses of 3 and 9 mg siRNA/kg, the nanoparticles are
well tolerated. At 27 mg siRNA/kg, elevated levels of blood urea
nitrogen and creatinine are observed that are indicative of kidney
toxicity. Mild elevations in alanine amino transferase and aspartate
transaminase at this dose level indicate that the liver is also
affected to some extent. Analysis of complement factors does not
reveal any changes that are clearly attributable to dosing with the
nanoparticle formulation. Detection of increased IL-6 levels in all
animals at 27 mg siRNA/kg and increased IFN- in one animal
indicate that this high dose level produces a mild immune re-
sponse. Overall, no clinical signs of toxicity clearly attributable to
treatment are observed. The multiple administrations spanning a
period of 17–18 days enable assessment of antibody formation
against the human Tf component of the formulation. Low titers of
anti-Tf antibodies are detected, but this response is not associated
with any manifestations of a hypersensitivity reaction upon read-
ministration of the targeted nanoparticle. Taken together, the data
presented show that multiple, systemic doses of targeted nano-
particles containing nonchemically modified siRNA can safely be
administered to non-human primates.
systemic administration  RNA interference
A fundamental cellular mechanism for inhibiting gene ex-pression, RNAi has quickly become a standard for drug
discovery research. If therapeutics that are based on RNAi can
be developed, they will have the potential to work on all classes
of molecular targets, including many that are not treatable with
conventional small molecules, antibodies, or other biologic
agents (1). Synthetic siRNAs that are double-stranded and 21–23
nt in length use the naturally occurring RNAi process and are
being explored as potential therapeutics in human clinical trials
(1, 2). These trials involve localized delivery to the eye, nose, and
lung (1). An important goal for siRNA-based drugs is targeted,
systemic administration, and effective delivery of siRNA is likely
the most challenging barrier to the widespread application of
RNAi-based therapeutic use in humans.
Naked siRNA is unstable in plasma, and chemical modifica-
tions that impart in vivo stability have been used systemically in
animal models (3, 4). In these studies, the siRNA doses were
30–50 mg/kg in mice. Such large doses may be contraindicated
for therapeutic applications in humans because of costs and
safety issues (5). However, encapsulation of the siRNA in
lipid-based nanoparticles of 100-nm diameter provided effec-
tive dosing in mice (5, 6) and monkeys (6) at amounts 1–3
mg/kg. These delivery systems did not contain targeting ligands,
and the siRNA was shown to accumulate in the liver where it
inhibited protein expression.
Numerous studies have used ligand-targeted siRNA (7). An-
tibody (8) and aptamer (9, 10) targeting agents have been
investigated in mouse models (8, 9). These conjugates carry10
siRNA molecules per targeting agent. Alternatively, ligand-
containing nanoparticles have been used (7) and have adjustable
ligand numbers and larger siRNA payloads. For example, 70-nm
nanoparticles can contain 1–100 transferrin (Tf)-targeting li-
gands and 2,000 siRNA molecules, yielding siRNA/targeting
ligand ratios of 20:1 or higher (11). Nanoparticles containing
multiple targeting ligands can have multivalent binding to cell
surfaces and deliver a larger payload of siRNA than molecular
conjugates.
No reports of targeted delivery of siRNA in non-human
primates have appeared to our knowledge. Naked siRNA has
been administered to rhesus macaques through intranasal instil-
lation (12), and lipid-formulated siRNA was injected via the
saphenous vein (single injection only) into cynomolgus monkeys
(6). Numerous investigations of targeted, systemic delivery of
siRNA using mouse models have been reported. Those studies
raise issues of concern for the safe administration of multiple
doses of targeted, systemic delivery of siRNA. Although naked
siRNA is not inherently immunostimulatory (13), lipid delivery
of double-stranded siRNA and single-stranded RNA can stim-
ulate the immune systems of mammals (14–16). Lipid-based
endosomal delivery of siRNA containing immunostimulatory
motifs activate Toll-like receptors (TLRs), such as TLR7, TLR8,
and TLR9, in peripheral blood mononuclear cells, monocytes,
plasmacytoid dendritic cells, nonplasmacytoid dendritic cells
(14–16), and CD34 progenitor cells (17). Fortunately, chemi-
cally modified siRNAs can be prepared that minimize their
immunostimulatory behavior (18). Interestingly, the delivery of
siRNA via the cyclodextrin polycation system developed in our
laboratory at the California Institute of Technology did not
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produce immune stimulation in mice, even when the siRNA
contained a highly stimulatory base sequence motif (19). Pos-
sible reasons for the lack of immune stimulation include endo-
somal buffering by this delivery system (20, 21) [inhibitors of
endosomal acidification have been shown to block immune
activation (16)] and lack of uptake by specific immunocompetent
cell populations (this system does not enter CD34 progenitor
cells; J.D.H. and J. J. Rossi, unpublished data).
Targeted, systemic delivery vehicles contain a targeting ligand,
and our investigations have shown that our formulations can be
sterically stabilized by PEG (11, 19). PEGylated lipid systems
carrying small molecule drugs have been used clinically for years,
and these lipid-based systems are capable of causing hypersen-
sitivity reactions and complement activation (22, 23). Addition-
ally, repeated administration of lipid-based delivery vehicles has
the potential to cause phospholipidosis (24) and other lipid-
related toxicities. Recently, PEGylated liposomes have been
shown to have accelerated clearance from blood and can elicit
acute hypersensitivity upon repeated dosing that is caused by a
long-lived antibody response generated against the PEGylated
particle (25–28). Thus, the safety of targeted, systemic delivery
vehicles containing siRNA will require multidosing studies to
properly assess their behavior.
We have been investigating a cyclodextrin polycation delivery
system that is capable of targeted, systemic delivery of siRNA in
mice (19). Here, we report on a multidosing study of siRNA in
non-human primates with a targeted, systemic delivery system.
The results of this investigation suggest that this delivery system
can be safely used for repeated systemic administration of
siRNA.
Results and Discussion
Nanoparticles Containing Tf-Targeting Ligand and siRNA Are Active in
Mouse, Monkey, and Human Systems.Fig. 1 schematically illustrates
the delivery system and its formulation with siRNA to prepare
targeted nanoparticles; these nanoparticles use human Tf as the
targeting ligand. This targeted particle has been shown to reach
tumors from an i.v. injection in mice (19, 29) and give sequence-
specific gene inhibition that leads to antitumor efficacy (19). The
Tf receptor (TfR) has long been known to be up-regulated in
malignant cells (30). Tf targeting to TfR has been used for drug
delivery in human clinical trials with adriamycin (31) and
cisplatin (32) and is currently in a phase III trial for brain cancer
with diphtheria toxin (33). Human Tf can bind to the TfR in
mouse, rat andmonkey [data provided in supporting information
(SI) Fig. 6] and therefore provides a useful targeting agent for
use in these species without a change in formulation when
proceeding to dosing in humans. The particles formed are 70
nm in diameter (11) and have been shown to localize and
penetrate throughout tumors in a metastatic mouse model of
Ewing’s sarcoma (19). The siRNA sequence is a potent inhibitor
of the M2 subunit of ribonucleotide reductase (RRM2) (34) and
is active in mouse, monkey, and human cells (ref. 34 and SI Fig.
7). The cross-species function of both the targeting ligand and
the siRNA allows for studies in rodents and non-human primates
by using the exact formulation proposed for use in humans.
Non-Human Primate Study Design. Fig. 2 outlines the in-life study
in three female cynomolgus monkeys, including dosing and
blood sampling schedules. For treatment phases 2–4, dosing of
animal 1 was performed 1 day ahead of the other two animals
to allow a 24-h monitoring period for each escalating dose level
before further animal treatment. All animals successfully re-
ceived all doses shown in Fig. 2. The 27-mg/kg dose is very large
for a formulated siRNA. For example, this amount is equivalent
to a mouse dose (adjusted for body surface area in mg/m2) of 109
mg/kg. Typical dosing amounts in formulations of siRNA in mice
(including the cyclodextrin system) are 1–5 mg/kg (5, 6, 19).
Thus, the 27-mg/kg dose is20–100 times larger than those that
have shown efficacy in mouse models (when doses are extrap-
olated across species on a body surface area basis). After the
27-mg/kg dosing, a washout period of 11–12 days was provided
to allow for the possible formation of anti-Tf antibodies. Final
dosing at 3 mg/kg was performed at a time when antibodies may
be present and their effects on the animal and/or siRNA
pharmacokinetics (PK) could be evident.
Clinical Signs, Body Weight, and Food Consumption. Clinical obser-
vations considered potentially treatment-related were limited
mainly to the highest dose level (27 mg/kg) and included dry or
hard feces and apparent inappetence. Hard feces were observed
in the cage pans of all animals upon the initial observation after
the phase 4 dosing (27 mg/kg). All animals exhibited inappetence
(low biscuit consumption) at the initial observation after phase
4 (27 mg/kg) dosing. This observation is consistent with the
findings of a loss of body weight and decrements in food
consumption, as discussed below. However, these events were
not clearly treatment-related.
There was no effect on food consumption. Sporadically low
biscuit consumption was not temporally related to dosing with
the test material and was attributed to inappetance caused by
excitement or stress of the study animals because of the intensive
study procedures (i.e., the repeated restraint for dosing, activity
in the animal room, and the intensive blood sampling schedule).
A slight decrease in body weight occurred in the animals over the
course of the study, but this change was considered secondary to
the inappetance that was most likely stress-related.
Assessment of Hematology, Serum Chemistry, Coagulation Parame-
ters, Complement Parameters, Antibodies, and Cytokines. Blood
samples were collected at the times indicated in Fig. 2 and used
Fig. 1. Schematic illustration of the delivery system (A) and its formulation
with siRNA (B).
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to assess hematology, serum chemistry, coagulation, comple-
ment activation, immune and antibody responses, and PK. All
hematological parameters remained within the range of the
predosing values and the normal ranges for monkeys, except two
animals had slightly elevated mean platelet volume (11.1 and
11.9 fl, compared with 8.0 fl prestudymean) and lowered platelet
counts (196 and 280  103/l, vs. 549  103/l prestudy mean)
24 h after receiving the 27-mg/kg dose.
Serum chemistry values all remained within range of the
predosing values except for aspartate transaminase (AST), ala-
nine amino transferase (ALT), blood urea nitrogen (BUN), and
creatinine (CRE) 24 h after receiving the 27-mg/kg dose (Table
1). The increases in BUN and CRE are indicative of toxicity to
the kidney. Because the formulation without siRNA was not
tested in this study, it is uncertain whether the apparent renal
toxicity was caused by the siRNA or one or more of the
formulation constituents. It is unlikely that the kidney toxicity is
related to the siRNA based on unpublished experience with i.v.
injection of large doses of naked siRNAs. The mild increases in
AST and ALT (2-fold, relative to prestudy) suggest that there
may be some effect on the liver at the highest dose level.
However, the increases are well below the range that would be
associated with significant hepatotoxicity.
Coagulation parameters (prothrombin time, activated partial
thromboplastin time, and fibrinogen) were not substantially
affected by the targeted nanoparticles, even at the highest dose
level tested (Table 1). Prothrombin time was very slightly
prolonged in one animal on day 11, activated partial thrombo-
plastin time was also slightly prolonged in all animals on days
10/11 (1 day after the 27-mg/kg dose), and fibrinogen concen-
tration was slightly decreased in all animals on the same day.
However, these changes were small in magnitude and did not
deviate from the normal ranges for monkeys; hence, they could
not be clearly distinguished from normal variation.
Overall, the evaluation of hematological, coagulation, and
serum chemistry parameters indicated that the targeted nano-
particles were well tolerated, except at the 27-mg/kg dosing level
where there were some indications of an impact on the animals.
The most noteworthy change was the increase in BUN and CRE
indicative of renal dysfunction.
Fig. 2. Overview of experimental protocol. Three female, non-naı¨ve cynomolgus monkeys were treated with an siRNA-containing nanoparticle formulation.
Formulations were freshly prepared on the day of treatment and had a final siRNA concentration of 1 mg/ml. A simple slow-push i.v. injection was used to
administer the 3-mg/kg (with respect to siRNA) and 9-mg/kg doses. The large volume needed for the 27-mg/kg dose required administration of this dose by 2-h
i.v. infusion; the 0-mg/kg dose (D5W only) was also delivered by infusion. The 0-, 3-, 9-, and 27-mg/kg doses were administered sequentially, with 2–3 days
between each dose, as indicated. After the 27-mg/kg dosing, a washout period of 11–12 days was allowed before a final 3-mg/kg dose was given. Blood samples
were drawn at the indicated times for analyses of complete blood counts, serum chemistry, coagulation parameters, complement factors, antibodies, cytokines,
and PK.









mg/dl PT, s APTT, s
Fibrinogen,
mg/dl
Acclimation 31  6 38  24 16  6 0.8  0.2 10.0  0.2 18.7  1.7 296  63
D5W 33  6 33  8 15  5 0.8  0.1 11.0  0.1 18.1  1.1 286  31
3 mg/kg * * 13  3 0.7  0.1 11.5  1.2 21.3  1.9 289  77
9 mg/kg 41  7 88  71 12  3 0.8  0.1 10.4  0.4 21.5  2.5 230  22
27 mg/kg 79  26 90  26 29  9 4.0  2.3 12.6  3.6 23.3  2.9 197  11
Data were collected 24 h after each dose. PT, prothrombin time; APTT, activated partial thromboplastin time.
*At this dose level, one animal gave elevated levels that were not observed upon subsequent higher doses. Animal
1: AST 27 units/liter, ALT 24 units/liter; animal 2: AST 39 units/liter, ALT 55 units/liter; animal 3: AST 534
units/liter, ALT  600 units/liter.




















Table 2 lists data that show there was no complement activa-
tion by the targeted nanoparticles. Neither Bb nor CH50 exhib-
ited significant changes at any dose level, relative to predose
values, suggesting that both the classical and alternative com-
plement pathways were not highly activated. The slight reduction
in mean CH50 5 min after the 27-mg/kg dose (relative to the
predose mean) was within the range of normal variation. Al-
though an effect of the 27-mg/kg dose could not be ruled out, this
difference was considered most likely a reflection of stress in the
animals, as slight complement activation can occur from stress.
It is important to test for complement activation in non-human
primates, which is one of the main reasons for investigating our
targeted nanoparticles in this species. Oligonucleotides have
shown species-specific responses between rodents and non-
human primates (35), and antisense molecules encapsulated in
cationic liposomes have revealed complement activation in
cynomologous monkeys that was not observed in rabbits (36).
The lack of complement activation observed from the targeted
nanoparticles even at doses as high as 27 mg/kg suggests that
complement activation will not be dose-limiting and correlates
well with in vitro studies that revealed minimal complement
activation (11).
Assessment of Immune Responses to the Targeted Nanoparticles.
Cytokines were measured that can provide indications of T
helper 1 (IL-12, IFN-), T helper 2 (IL-10, IL-4), and inflam-
matory responses (IL-6, TNF-). IL-10, IL-4, and TNF- levels
were below the lower limits of quantification (1.8, 14.9, and 4.8
pg/ml, respectively) for all samples. The data for IL-12, IFN-
and IL-6 are shown in Fig. 3. Elevated levels of IL-6 were
observed in all three animals at the 27-mg/kg dose. Increasing
amounts of IL-12 and IFN- were observed in one monkey at 9
and 27 mg/kg, respectively. However, the increases in these
cytokines were not quantitatively impressive or suggestive of
intensive immune stimulation. Taken together, these data sug-
gest that targeted nanoparticles do not cause immune responses
of significance at doses of 3 and 9 mg/kg (siRNA content),
whereas modest elevation in specific cytokines was observed at
the 27-mg/kg dose. Of importance is the fact that the siRNA used
here is not chemically modified. We have shown that targeted
delivery of siRNA that is not chemically modified can be
accomplished in mice without immune stimulation, even when
the siRNA contains a known immunostimulatory motif (19). In
the present study, we observed a suggestion of limited immu-
nostimulation in monkeys at a high dose level associated with
other manifestations of toxicity, and under conditions of re-
peated (escalating) doses.
Multiple Doses of Targeted Nanoparticles Safely Administered in
Non-Human Primates. The hematological, serum, coagulation,
complement activation, and cytokine parameter data taken
together show that multiple doses of the targeted nanoparticles
can be safely administered to non-human primates. Recently,
work published by Grimm et al. (37) and Formstecher et al. (38)
highlights the effects of saturating the RNAi pathways. Grimm
et al. used expressed short hairpin RNAs in the liver of mice,
whereas Formstecher et al. used synthetic siRNAs in vitro. Here,
we do not observe physiological signs of toxicity that would
suggest that the RRM2 siRNA is having negative effects on
healthy tissue. Additionally, the safety of the nanoparticles at
levels far above the amounts that were efficacious in mouse
studies [0.5–1.0-mg/kg equivalents in monkey doses when ex-
trapolated across species on a body surface area basis (19, 39)]
Table 2. Complement analyses
Sample Bb, g/ml CH50, units/ml
Predose 0.6  0.2 242  29
D5W–5 min 0.7  0.2 216  32
D5W–1 h 0.8  0.3 252  41
Predose 0.7  0.0 270  62
3 mg/kg–5 min 0.7  0.1 245  45
3 mg/kg–1 h 1.0  0.2 256  56
Predose 0.9  0.2 196  34
9 mg/kg–5 min 0.9  0.1 170  45
9 mg/kg–1 h 1.0  0.0 241  29
Predose 0.9  0.1 254  106
27 mg/kg–5 min 1.0  0.1 185  95
27 mg/kg–1 h 0.9  0.1 247  119
Fig. 3. Cytokines. At 6 h postdosing, blood was drawn from each animal,
processed into plasma, and analyzed for the indicated cytokine levels via ELISA
(IL-6 and IL-12) or multiplex assay (IFN-). Experimentally determined lower
limits of quantification values were 12 ng/ml for IL-12, 11.9 pg/ml for IFN-,
and 7.8 ng/ml for IL-6. Bars indicate averages, and error bars indicate standard
deviations for each group of n  3 measurements (one for each of the three
animals).
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suggests that there should be a large therapeutic index (ratio of
the lethal dose of 50% of the study population divided by the
effective dose of 50% of the study population) for the targeted
nanoparticles, even when using multidosing schedules.
Zimmermann et al. (6) have reported single doses of nontar-
geted, lipid-formulated siRNAs in cynomolgus monkeys. At dose
levels of 2.5 mg siRNA/kg, only elevated AST and ALT levels
were observed. However, the values of AST and ALT at 48 h
after dosing were remarkably high (1,555  1,727 and 1,167 
1,157, respectively) and consistent with significant hepatocellu-
lar toxicity, which suggests that the 2.5 mg siRNA/kg dose of that
formulation is near or above the maximum tolerated single dose
in monkeys. No similar serum enzyme increases were observed
at a 1.0 mg siRNA/kg dose in that study, which suggests that the
dose–response for hepatotoxicity may be relatively steep. By
comparison, the nanoparticle delivery system tested in the
present study was not associated with any indications of organ
dysfunction or significant toxicity at siRNA doses up to 9 mg/kg.
Antibody Formation and PK.Fig. 4A shows data that reveal low titer
antibody formation was obtained from all three animals. These
antibodies react with the Tf on the nanoparticle, as their binding
can be inhibited by the presence of Tf (Fig. 4B). Because
antibody binding to the nanoparticle can be inhibited by Tf, it is
suggestive that the antibodies are not binding to the PEGylated
particle, but rather the human Tf. The antibody response is small
and does not produce any manisfestations of a hypersensitivity
reaction upon readministration of the targeted nanoparticles.
Pharmacokinetic measurements provide an indication of the
circulating half-life of the siRNA-containing nanoparticles and
whether or not neutralizing antibodies cause accelerated blood
clearance. The hybridization assay that was applied is specific for
the antisense strand of the RRM2 siRNA (these assays are, by
their nature, strand-specific, as sample processing causes strand
separation of the RNA duplex). However, gel electrophoresis of
selected monkey plasma samples revealed that the duplex siRNA
remained encapsulated within the nanoparticles (data not
shown). Thus, the hybridization assay yielded information on the
plasma concentration of the siRNA that was associated with
nanoparticles. The bioanalytical method includes a detergent
treatment step that disrupts the nanoparticles and releases the
siRNA. This method was used for analyzing monkey plasma
samples taken predose and 5 min, 30 min, 2 h, and 6 h postdose
(Fig. 5A). All three animals exhibit dose-dependent siRNA
Fig. 4. Detection of monkey antibodies against human Tf. (A) Total antin-
anoparticle antibody titer was determined by ELISA on serum samples taken
predosing (acclimation) and on day 18. (B) Serum samples (day 18) were
incubated with human holo-Tf (1 or 100g/ml) or HSA (1 or 100g/ml) before
antibody titer determination by ELISA. Incubation with HSA had a minimal
effect on the ELISA signal, whereas there was a sharp dose-dependent reduc-
tion in the ELISA signal upon Tf incubation. This result supports the rationale
that the antibodies generated specifically recognize the Tf moiety of the
AD-PEG-Tf component of the nanoparticles.
Fig. 5. PK of nanoparticles in monkey plasma. (A) Total plasma siRNA (ng/ml)
was determined in monkey plasma as a function of time after dosing by
hybridization-ligation assay. In all three animals, the t  5 min plasma level
scales with dose. Points represent the mean value for three animals, and error
bars denote standard deviations. For all measurements below the lower limit
of quantification (LLOQ), a value equal to half of the LLOQ (LLOQ/2) is
reported. (Note: As discussed in Results and Discussion, there is reason to
believe these values are underestimates of true circulating nanoparticle con-
centrations.) (B) Total plasma siRNA (ng/ml) concentrations at t  5 min
postdose. There is no clear difference observed between the initial (days 3 or
4) and final (day 21) 3-mg/ml dose across the three animals, suggesting that
there may not be a reduction in half-life resulting from anti-Tf antibodies.




















levels in plasma at the first (5 min) time point and relatively rapid
clearance. Bellocq et al.¶ used this delivery system to deliver
plasmids containing the human p53 gene into tumors of mice. In
that study, PCR was used to determine the PK and biodistribu-
tion of the plasmid in whole blood after i.v. injection. The dose
was equivalent to 2.5-mg/kg plasmid content in a monkey, scaled
on a body surface area basis. It was found that, at 1 h postin-
jection, 1.4% of the injected dose was in the blood and that it
declined to 0.01% at 24 h. That dose provided tumor delivery of
plasmid DNA and detectable p53 mRNA (by RT-PCR) in the
tumor at 24 h postinjection.¶ The work of Bellocq et al. is
consistent with the data here with respect to the indications of
rapid blood clearance of the nanoparticles. Very recently, Sato
et al. (41) reported that galactose-containing liposomes (in-
tended for directed uptake by the liver) are quickly eliminated
from the blood of mice after i.v. injection. Those investigators
measured the siRNA in whole blood, not plasma. Thus, targeted
nanoparticle systems appear to be rapidly removed from the
circulation, most likely owing to the intended tissue targeting.
A comparison of the amounts of siRNA measured at 5 min
after the initial and final 3-mg/kg doses (Fig. 5B) showed no
significant differences between these dosing occasions, suggest-
ing that there was no antibody-mediated acceleration of nano-
particle clearance. However, because of the limited number of
animals and data points, a firm conclusion cannot be drawn
regarding the possible influence of anti-Tf antibody formation
on nanoparticle kinetics; further experiments that address this
issue need to be performed. Also, it is important to note that no
adverse reactions were observed in the animals from the final
3-mg/kg dose when antibodies were present. This result contrasts
with the adverse reactions observed with repeated administra-
tion of lipid-based systems that are associated with the presence
of antibodies (22, 23, 25–28).
Materials and Methods
Formulation of Targeted, siRNA-Containing Nanoparticles. The tar-
geted, nanoparticle formulation used here is the same as was
used to show sequence-specific gene knockdown in mice at 2.5
mg/kg (19). The delivery system uses three components [cyclo-
dextrin-containing polycation (CDP), adamatane (AD)-PEG,
and AD-PEG-Tf; see Fig. 1] that are a physical mixture of 1:1
AD/-CD (mol/mol) and AD-PEG/AD-PEG-Tf of 1:1,000 (wt/
wt) (19). The mixture was added to an equal volume [all in 5%
(wt/vol) glucose (D5W)] of siRNA (see Fig. 1) at a charge ratio
(positive charges from CDP to negative charges from siRNA
backbone) of 3:1 (). Human holo-Tf was used as the targeting
agent and is able to bind to mouse, rat, and monkey TfR (data
provided in SI Fig. 6).
siRNA. Synthetic siRNA (nonchemically modified) was purchased
in gram quantities from Qiagen (Valencia, CA). The sequence
used was: 5-gauuuagccaagaaguucagu-3 (sense) and 3-
cgcuaaaucgguucuucaagu-5 (antisense).
This siRNA targets the RRM2 (34). This sequence has been
shown to be a potent inhibitor of the RRM2 protein and exhibits
significant antiproliferative activity in cancer cells of varying
human types and species (mouse, rat, and monkey) (34). Anti-
proliferation data for human and monkey cancer cell lines are
given in SI Fig. 7.
Treatment of Monkeys with Targeted, siRNA-Containing Nanopar-
ticles. All procedures involving cynomolgus monkeys were per-
zoutf;Fn2formed by a contract research organization in accor-
dance with applicable laws and regulations and under the
guidance of the Institutional Animal Care and Use Committee.
Animals received sequential single doses of nanoparticles at 0
(D5W only), 3, 9, and 27 mg/kg (with respect to siRNA content)
according to the schedule depicted in Fig. 2; all formulations
were prepared freshly on the day of injection at an siRNA
concentration of 1 mg/ml. The 3- and 9-mg/kg injections were
made via a standard ‘‘slow push’’ i.v. injection. The 27-mg/kg
injection necessitated a dosing volume such that an i.v. infusion
(2 h) was required; the 0-mg/kg (D5W only) dosing was done
with the same volume and in the same fashion (2-h infusion) as
the 27-mg/kg dosing. Each escalating dose was given after a 2- to
3-day washout period. After the 27-mg/kg dose was adminis-
tered, an 11- to 12-day washout period was implemented to allow
sufficient time for a possible antibody response to develop before
one final 3-mg/kg dose.
Blood samples were taken at various time points relative to
each of the doses and processed appropriately to allow numerous
assessments, as described below. For hematology and coagula-
tion, blood samples were taken once during acclimation (before
the initial 0-mg/kg dosing) and 24 h postdose for the 0-, 3-, 9-,
and 27-mg/kg doses; citrated plasma was obtained from whole
blood for measurement of coagulation parameters. For serum
chemistry, blood samples were taken once during acclimation
and 24 h postdose for the 0-, 3-, 9-, and 27-mg/kg doses; serum
was obtained from whole blood for measurement of serum
chemistry parameters. For complement analyses, blood samples
were taken predose and 5 min and 1 h postdose for the 0-, 3-, and
9-mg/kg doses and predose, immediately postinfusion, and 1 h
postinfusion for the 27-mg/kg dose (given by 2-h infusion). The
timing of the sampling for complement factors was based on the
known propensity for activation to occur acutely in relation to
oligonucleotide or excipient blood concentrations (i.e., when
observed with i.v. injection of unformulated oligonucleotides or
various other complement-activating formulations).
Analyses of Monkey Blood Samples. Hematology and coagulation.
Hematological measurements were made on whole blood placed
in an EDTA-treated tube and analyzed with an Advia 120
automated analyzer (Bayer Diagnostics, Terrytown, NY). Mea-
sured hematology parameters included erythrocyte count, he-
matocrit, hemoglobin concentration, leukocyte count (including
five-part differential), mean platelet volume, mean corpuscular
volume, mean corpuscular hemoglobin, mean corpuscular he-
moglobin concentration, platelet count, red cell distribution
width, and reticulocyte count. Coagulation parameters evalu-
ated in citrated plasma samples were assessed with a STACom-
pacy automated analyzer (Roche Centralized Diagnostics, Basel,
Switzerland); the measured coagulation parameters include
activated partial thromboplastin time, prothrombin time, and
fibrinogen.
Serum chemistry. Serum chemistry determinations were made with
an AU400 automated analyzer (Olympus, Melville, NY). The
measured serum chemistry parameters included albumin/
globulin ratio, albumin, ALT, alkaline phosphatase, AST, bili-
rubin (total), BUN, calcium, chloride, cholesterol (total), CRE,
creatine kinase, gamma glutamyl transferase, globulin, glucose,
phosphoruc (inorganic), potassium, protein (total), sodium, and
triglyceride.
Complement factors. Plasma Bb levels were determined by ELISA;
serum CH50 values were determined by a standard sheep eryth-
ryocyte lysis-based assay.
Antibody analysis. An ELISA was created in which 96-well plates
were coated with Neutravidin and then treated with biotinylated
nanoparticles. Nanoparticles were prepared as above using AD-
PEG-Tf that had been biotinylated (1–5 biotins per AD-PEG-Tf)
using a commercially available kit (Pierce, Rockford, IL). Ani-
mal serum samples were placed in nanoparticle-treated plates,
followed by subsequent addition of HRP-conjugated protein
¶Bellocq NC, Davis ME, Engler H, Jensen GS, Liu A, Machemer T, Maneval DC, Quijano E, Pun
SH, Schluep T, Wen S (2003) Mol Ther 7:S290 (abstr).
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A/G and the HRP substrate TMB. Absorbance measurements
were made at 450 nm. A rabbit anti-human Tf anti-serum (Bethyl
Laboratories) containing 1 mg/ml anti-human Tf polyclonal
antibody was used as a positive control and to create a calibration
curve. For competitive ELISA analyses, animal sera were incu-
bated with either 1 or 100 g/ml Tf or human serum albumin
(HSA) before delivery to nanoparticle-treated plates.
Cytokines. Serum IL-6 and IL-12 levels were determined by using
commercially available ELISA kits (Invitrogen, Carlsbad, CA).
Serum IFN-, IL-10, IL-4, and TNF- levels were determined by
using commercially available multiplex kits and a Luminex
instrument (Invitrogen).
PK. Plasma concentrations of the siRNA were determined by
using a modified hybridization-ligation assay (40). The method
was partially validated for accurate quantification of both naked
and nanoparticle-contained siRNA from monkey plasma.
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